Targeted Therapy for Cancer: Key Questions to Ask Your Oncologist

Targeted therapy has reshaped oncology by attacking cancer cells based on specific genetic or molecular profiles. Unlike traditional chemotherapy, these drugs aim to interfere with pathways that drive tumor growth while sparing many healthy cells. As the field accelerates, patients and clinicians alike face a growing list of decisions—from testing requirements to managing resistance. A careful, informed dialogue with the treating oncologist has become essential.

Recent Trends in Targeted Therapy

The pace of biomarker discovery has expanded the pool of actionable mutations across common cancers, including lung, breast, colorectal, and melanoma. Combination regimens—pairing targeted agents with immunotherapy or other targeted drugs—are now common in clinical trials and real-world practice. Regulators continue to grant accelerated approvals for drugs that show durable responses in biomarker-defined subgroups, pushing molecular testing into earlier lines of treatment.

• Liquid biopsy adoption is rising, allowing non-invasive monitoring of circulating tumor DNA.
• Comprehensive genomic profiling is increasingly recommended over single-gene tests.
• Drug developers are designing next-generation inhibitors to overcome acquired resistance.

Background: How Targeted Therapy Differs from Traditional Treatments

Standard chemotherapy acts on rapidly dividing cells broadly, whereas targeted agents block specific molecules involved in cancer growth, progression, or blood vessel formation. This precision requires a tumor sample or blood test to identify the relevant alteration. Not all patients are eligible; a mismatch can mean no benefit and unnecessary side effects. The concept of “oncogene addiction” underlies many targeted approaches—cancer cells become dependent on a single mutated pathway, and disrupting that pathway can produce dramatic, albeit often temporary, tumor shrinkage.

Key Concerns for Patients

Patients considering targeted therapy frequently encounter uncertainty about effectiveness, toxicity, and follow-up. The following questions are commonly discussed during oncology consultations:

• Which biomarker test is appropriate for my cancer type, and how is the sample obtained?
• Is the targeted drug approved for my specific mutation, or am I eligible for a clinical trial?
• What are the expected side effects—both common and rare—and how are they managed?
• What is the likelihood of eventual resistance, and is there a plan if the drug stops working?
• How will the therapy affect my daily life, including work, travel, and other medications?
• What are the out-of-pocket costs, and does insurance typically cover this treatment?

“Because targeted therapy is often used in advanced or metastatic settings, patients need to understand the goals—shrinkage, stabilization, or symptom control—rather than assuming a cure.”

Likely Impact on Treatment Planning

The growing reliance on molecular profiling is shifting cancer care toward shared decision-making. Oncologists now incorporate genomic results into timing of therapy, sequence of agents, and surveillance intervals. Patients who ask targeted questions are more likely to receive tailored monitoring for resistance markers and to discuss early switch strategies. However, access remains uneven—patients in community settings may not receive timely comprehensive testing, and disparities in insurance coverage can limit options. The impact is most pronounced when a clear, actionable mutation is identified early in the disease course.

What to Watch Next

Several developments are poised to change how targeted therapy advice is delivered. First, the integration of artificial intelligence into pathology and genomic interpretation may flag rare mutations that are currently overlooked. Second, the expansion of basket trials—which enroll patients based on mutation rather than tumor site—could broaden indications for existing drugs. Third, the emergence of oral targeted agents with manageable toxicity profiles may allow more home-based care, reducing clinic visits.

• Watch for updates on FDA approvals of new targeted combinations in 2025 and beyond.
• Pay attention to real-world evidence from registries tracking resistance patterns and long-term outcomes.
• Observe how reimbursement policies evolve for liquid biopsy and comprehensive genomic profiling.